شبكة المعلومات الجامعية

التوثيق الإلكتروني والميكروفيلم

بسم الله الرحمن الرحيم

HANAA ALY

شبكة المعلومات الجامعية

التوثيق الالكتروني والميكروفيلم

HANAA ALY

شبكة المعلومات الجامعية

التوثيق الإلكتروني والميكروفيلم

جامعة عين شمس

التوثيق الإلكتروني والميكروفيلم

قسم

نقسم بالله العظيم أن المادة التي تم توثيقها وتسجيلها
علي هذه الأقراص المدمجة قد أعدت دون أية تغيرات

يجب أن

تحفظ هذه الأقراص المدمجة بعيدا عن الغبار

HANAA ALY

The Effect of Itraconazole on the Clinical Outcomes of Patients with Advanced Non Small Cell Lung Cancer Receiving Platinum Based Chemotherapy

Thesis

Submitted for Partial Fulfilment of MD Degree in Clinical Oncology & Nuclear Medicine

By

Asmaa Waheed Mohamed Mostafa

Under supervision of

Prof. Mohamed Mohamed El Bassiouny

Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University

Dr. Dalia Abd El Ghani El-khodary

Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University

Dr. Amr Shafik Tawfik

Assistant Professor of Clinical Oncology and Nuclear Medicine
Faculty of Medicine - Ain Shams University

Faculty of Medicine – Ain Shams University

2020


Lets start everything with
Bismillah

Acknowledgment

First and foremost, I feel always indebted to ALLAH, *the Most Kind and Most Merciful.*

I'd like to express my respectful thanks and profound gratitude to **Prof. Mohamed Mohamed El Bassiouny,** *Professor of Clinical Oncology and Nuclear Medicine - Faculty of Medicine- Ain Shams University for his keen guidance, kind supervision, valuable advice and continuous encouragement, which made possible the completion of this work.*

I am also delighted to express my deepest gratitude and thanks to **Dr. Dalia Abd El Ghani El-khodary,** *Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for her kind care, continuous supervision, valuable instructions, constant help and great assistance throughout this work.*

I am deeply thankful to **Dr. Amr Shafik Tawfik,** *Assistant Professor of Clinical Oncology and Nuclear Medicine, Faculty of Medicine, Ain Shams University, for his great help, active participation and guidance.*

I wish to introduce my deep respect and thanks to **Dr. May Ahmed Shawki,** *Lecturer of Clinical Pharmacy, Faculty of Medicine, Ain Shams University, for her kindness, supervision and cooperation in this study and it's publication.*

I would like to express my hearty thanks to all my family for their support till this work was completed.

Last but not least my sincere thanks and appreciation to all patients participated in this study.

Asmaa Waheed Mohamed Mostafa

List of Contents

List of Tables

List of Tables (Cont...)

List of Tables *(Cont...)*

List of Tables *(Cont...)*

List of Figures

List of Figures *(Cont...)*

List of Abbreviations

Abb.	Full term
ABC	*ATP-binding cassette*
ABCB1	*Transporter B1*
ALK	*Anaplastic lymphoma kinase*
ALL	*Acute lymphoblastic leukemia*
AML	*Acute myeloid leukemia*
AMP	*Association for Molecular Pathology*
ASCO	*American Society of Clinical Oncology*
AUC	*Area under the curve*
BCC	*Basal cell carcinoma*
BRAF	*B-Raf proto-oncogene*
BSC	*Best supportive care*
CAP	*The College of American Pathologists*
ChT	*Chemotherapy*
CK5/6	*Cytokeratin-5/6*
CT	*Computed tomography*
DFS	*Disease-free survival*
EGFR	*Epidermal growth factor receptor*
EML4	*Echinoderm microtubule-associated protein-like 4*
EML4-ALK	*Transforming anaplastic lymphoma kinase fusion gene*
FDA	*US Food and Drug Administration*
F-FDG PET/CT	*F-Fluorodeoxyglucose positron emission tomography/computed tomography*
GCSF	*Granulocyte colony stimulating factor*
HR	*Hazard ratio*
HUVECs	*Human umbilical vein endothelial cells*

List of Abbreviations *(Cont...)*

Abb.	Full term
IASLC	*International Association for the Study of Lung Cancer*
IHC	*Immunohistochemistry*
ITZ	*Itraconazole*
KRAS	*Kirsten rat sarcoma viral oncogene homolog*
LC	*Lung cancer*
mTOR	*Mechanistic target of rapamycin*
NCCN®	*National Comprehensive Cancer Network*
NSCLC	*Non-small cell lung cancer*
OR	*Odds ratio*
ORR	*Objective response rate*
OS	*Overall survival*
PAHs	*Polycyclic aromatic hydrocarbons*
PD	*Progression disease.*
PD-1	*Programmed cell death 1*
PD-L1	*Programmed death ligand 1*
PFS	*Progression-free survival*
PM	*Pemetrexed*
PS	*Performance state*
PSA	*Prostate-specific antigen*
Qol	*Quality of life*
RCT	*Randomized controlled trial*
RD	*Regression disease.*
ROS1	*ROS proto-oncogene 1*
SCC	*Squamous cell carcinoma*
SCLC	*Small cell lung cancer*
SD	*Stable disease.*
SES	*Socio-economic status*